Major Histocompatibility Complex class I and II (MHC I and II) (MHC I/II)

Major Histocompatibility Complex (MHC) class I and II peptide-binding clefts on dendritic cell/tumor fusion cells serve as the functional interface for inducing potent anti-tumor immunity. These fusion cells are hybrid biological entities created by merging patient-derived dendritic cells (DCs) with tumor cells, thereby combining the professional antigen-presenting machinery of the DC with the entire repertoire of tumor-associated antigens (TAAs) [1][2]. The MHC class I clefts present endogenous tumor peptides to CD8+ cytotoxic T lymphocytes, while MHC class II clefts present exogenous-derived peptides to CD4+ helper T cells, ensuring a coordinated and comprehensive immune attack [3]. This approach is particularly significant in oncology because it allows for the presentation of multiple known and unknown neoantigens, potentially overcoming the immune evasion seen with single-antigen vaccines [4]. Clinical applications primarily involve personalized cellular vaccines for hematological malignancies like acute myeloid leukemia and various solid tumors, where the fusion cells act as the primary vehicle for T-cell education and activation [2][5]. References: [1] Avigan, D., et al. (2004) Cytotherapy; [2] Rosenblatt, J., et al. (2011) Blood; [3] Gong, J., et al. (2000) Nature Medicine; [4] UniProt Consortium, MHC Class I/II; [5] Kufe, D. (2009) Cancer Biology & Therapy.

Other names

Human Leukocyte Antigen (HLA) class I and IIMHC peptide-binding grooveAntigen-presenting cleftsMHC-I/II complex

Presentation of a broad spectrum of tumor-associated antigens (TAAs) and neoantigens to both CD4+ and CD8+ T cells to stimulate a polyclonal anti-tumor immune response.